Literature DB >> 1283927

Determination of optimum cutoff levels of plasma des-gamma-carboxy prothrombin and serum alpha-fetoprotein for the diagnosis of hepatocellular carcinoma using receiver operating characteristic curves.

S Fujiyama1, K Izuno, K Yamasaki, T Sato, K Taketa.   

Abstract

Optimum cutoff levels for plasma des-gamma-carboxy (abnormal) prothrombin (DCP) and serum alpha-fetoprotein (AFP) were determined by analyzing receiver operating characteristic (ROC) curves to discriminate between hepatocellular carcinoma (HCC) and benign hepatic conditions. Plasma DCP levels in 200 patients with HCC and 197 control patients with benign liver diseases were measured by an enzyme immunoassay with anti-DCP monoclonal antibodies, while serum AFP levels for both groups were measured by radioimmunoassay. From ROC curves and tangential lines with a slope of 1.0, the cutoff levels of DCP and AFP were determined to be 0.11 AU/ml and 150 ng/ml, respectively. Lowered cutoff levels of DCP did not improve the sensitivity, in contrast to the increased sensitivity obtained by lowering the specificity of AFP. The sensitivities and specificities determined in this study were close to the currently used values of 0.1 AU/ml for DCP and 200 ng/ml for AFP, justifying these cutoff levels for the differentiation of benign and malignant liver diseases.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1283927     DOI: 10.1159/000217781

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  8 in total

1.  Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients.

Authors:  Makoto Meguro; Toru Mizuguchi; Toshihiko Nishidate; Kenji Okita; Masayuki Ishii; Shigenori Ota; Tomomi Ueki; Emi Akizuki; Koichi Hirata
Journal:  World J Gastroenterol       Date:  2015-04-28       Impact factor: 5.742

2.  Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review.

Authors:  Ryosuke Tateishi; Haruhiko Yoshida; Yutaka Matsuyama; Norio Mine; Yuji Kondo; Masao Omata
Journal:  Hepatol Int       Date:  2007-12-29       Impact factor: 6.047

3.  Performance of serum α-fetoprotein levels in the diagnosis of hepatocellular carcinoma in patients with a hepatic mass.

Authors:  Stephen L Chan; Frankie Mo; Philip J Johnson; Deyond Y W Siu; Michael H M Chan; Wan Y Lau; Paul B S Lai; Christopher W K Lam; Winnie Yeo; Simon C H Yu
Journal:  HPB (Oxford)       Date:  2013-08-26       Impact factor: 3.647

4.  Clinical evaluation of urinary transforming growth factor-beta1 and serum alpha-fetoprotein as tumour markers of hepatocellular carcinoma.

Authors:  J F Tsai; J E Jeng; L Y Chuang; M L Yang; M S Ho; W Y Chang; M Y Hsieh; Z Y Lin; J H Tsai
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

5.  The influence of alcoholic liver disease on serum PIVKA-II levels in patients without hepatocellular carcinoma.

Authors:  Keun Hee Kang; Ji Hoon Kim; Seong Hee Kang; Beom Jae Lee; Yeon Seok Seo; Hyung Joon Yim; Jong Eun Yeon; Jong Jae Park; Jae Seon Kim; Young Tae Bak; Kwan Soo Byun
Journal:  Gut Liver       Date:  2015-03       Impact factor: 4.519

6.  Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma.

Authors:  Sang Joon Park; Jae Young Jang; Soung Won Jeong; Young Kyu Cho; Sae Hwan Lee; Sang Gyune Kim; Sang-Woo Cha; Young Seok Kim; Young Deok Cho; Hong Soo Kim; Boo Sung Kim; Suyeon Park; Hae In Bang
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

7.  The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis.

Authors:  Jiaxin Zhang; Guang Chen; Peng Zhang; Jiaying Zhang; Xiaoke Li; Da'nan Gan; Xu Cao; Mei Han; Hongbo Du; Yong'an Ye
Journal:  PLoS One       Date:  2020-02-13       Impact factor: 3.240

8.  Clinical evaluation of serum alpha-fetoprotein and circulating immune complexes as tumour markers of hepatocellular carcinoma.

Authors:  J F Tsai; J E Jeng; M S Ho; W Y Chang; Z Y Lin; J H Tsai
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.